Ruxolitinib treatment for GvHD in patients with myelofibrosis

Acute Graft-versus-Host Disease: Novel Biological Insights

(2016) Takanori Teshima et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

(2015) R Zeiser et al.   LEUKEMIA

How we treat chronic graft-versus-host disease

(2014) M. E. D. Flowers et al.   BLOOD

In search of the source of factor VIII

(2014) E. Tuddenham   BLOOD

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

(2014) S. Spoerl et al.   BLOOD

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

(2013) A. Heine et al.   BLOOD

Diagnosis and management of chronic graft-versus-host disease

(2012) Fiona L. Dignan et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment

(2011) Aliénor Xhaard et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

(2009) A. M. Alousi et al.   BLOOD